IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
0.8205
+0.0045 (0.55%)
Nov 17, 2026, 9:38 AM EST - Market open
IN8bio Employees
IN8bio had 20 employees as of September 30, 2026. The number of employees increased by 3 or 17.65% compared to the same quarter last year. That makes IN8bio the 38,428th largest employer in the world and 5,494th in the United States.
Employees
20
Change (1Y)
3
Growth (1Y)
17.65%
Revenue / Employee
n/a
Profits / Employee
-$970,250
Market Cap
8.87M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 20 | 3 | 17.65% |
| Jun 30, 2026 | 18 | 0 | - |
| Mar 31, 2026 | 18 | 0 | - |
| Dec 31, 2025 | 17 | -1 | -5.56% |
| Sep 30, 2025 | 17 | -1 | -5.56% |
| Jun 30, 2025 | 18 | -21 | -53.85% |
| Mar 31, 2025 | 18 | -16 | -47.06% |
| Dec 31, 2024 | 18 | -13 | -41.94% |
| Sep 30, 2024 | 18 | -13 | -41.94% |
| Jun 30, 2024 | 39 | 10 | 34.48% |
| Mar 31, 2024 | 34 | 6 | 21.43% |
| Dec 31, 2023 | 31 | 5 | 19.23% |
| Sep 30, 2023 | 31 | 5 | 19.23% |
| Jun 30, 2023 | 29 | 8 | 38.10% |
| Mar 31, 2023 | 28 | 7 | 33.33% |
| Dec 31, 2022 | 26 | 7 | 36.84% |
| Sep 30, 2022 | 26 | 13 | 100.00% |
| Jun 30, 2022 | 21 | 7 | 50.00% |
| Mar 31, 2022 | 21 | 7 | 50.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| Vistagen Therapeutics | 41 |
| BioLineRx | 24 |
| CalciMedica | 15 |
| Radiopharm Theranostics | 14 |
| Cellectar Biosciences | 11 |
| Ensysce Biosciences | 10 |
| Immuron | 8 |
INAB News
- 1 day ago - IN8bio announces updated clinical data from INB-200, INB-400 programs - TheFly
- 1 day ago - IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy - GlobeNewsWire
- 10 days ago - IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 11 days ago - IN8bio reports Q3 EPS (24c), consensus (34c) - TheFly
- 11 days ago - IN8bio Earnings release: Q3 2026 - Filings
- 11 days ago - IN8bio Quarterly report: Q3 2026 - Filings
- 7 weeks ago - IN8bio Transcript: Small-Cap Virtual Conference - Transcripts
- 7 weeks ago - IN8bio to Present at Sidoti Small-Cap Virtual Conference - GlobeNewsWire